On Mar. 10, 2021, Thermo Fisher Scientific announced more than $600 million in capital investments to expand its bioprocessing production capabilities through 2022.

These investments were expected to more than double the company’s manufacturing capacity and support customers ramp up to meet both the short-term demands related to COVID-19 as well as long-term efforts to develop new vaccines and biologics for other conditions.

With these investments, the company expects to create more than 1,500 new jobs across 11 manufacturing sites in the Americas, Europe and Asia.